Correction to “Systematic Study of Tissue Factor Expression in Solid tumors”

IF 1.9 Q4 ONCOLOGY Cancer reports Pub Date : 2024-07-23 DOI:10.1002/cnr2.2143

{"title":"Correction to “Systematic Study of Tissue Factor Expression in Solid tumors”","authors":"","doi":"10.1002/cnr2.2143","DOIUrl":null,"url":null,"abstract":"de Bono JS, Harris JR, Burm SM, Vanderstichele A, Houtkamp MA, Aarass S, Riisnaes R, Figueiredo I, Nava Rodrigues D, Christova R, Olbrecht S, Niessen HWM, Ruuls SR, Schuurhuis DH, Lammerts van Bueren JJ, Breij ECW, Vergote I. Systematic study of tissue factor expression in solid tumors. Cancer Reports. 2023;6:e1699.In Table 1 for the data reported in literature for HNSCC, the TF prevalence (%) should read “58%–100%.” The two references mentioned (Refs. 18 and 19 in the Supporting Information file; Supporting Information References) should read:18. Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi BW, Mortensen J, Forman JL, Sorensen AL, Jensen DH, Kjaer A, von Buchwald C. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer. 2017;17: 572.19. Wojtukiewicz MZ, Zacharski LR, Rucinska M, Zimnoch L, Jaromin J, Rozanska-Kudelska M, Kisiel W, Kudryk BJ. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost. 1999;82: 1659–1662.We apologize for this error.","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 7","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.2143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

de Bono JS, Harris JR, Burm SM, Vanderstichele A, Houtkamp MA, Aarass S, Riisnaes R, Figueiredo I, Nava Rodrigues D, Christova R, Olbrecht S, Niessen HWM, Ruuls SR, Schuurhuis DH, Lammerts van Bueren JJ, Breij ECW, Vergote I. Systematic study of tissue factor expression in solid tumors. Cancer Reports. 2023;6:e1699.

In Table 1 for the data reported in literature for HNSCC, the TF prevalence (%) should read “58%–100%.” The two references mentioned (Refs. 18 and 19 in the Supporting Information file; Supporting Information References) should read:

18. Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi BW, Mortensen J, Forman JL, Sorensen AL, Jensen DH, Kjaer A, von Buchwald C. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer. 2017;17: 572.

19. Wojtukiewicz MZ, Zacharski LR, Rucinska M, Zimnoch L, Jaromin J, Rozanska-Kudelska M, Kisiel W, Kudryk BJ. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost. 1999;82: 1659–1662.

We apologize for this error.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对 "组织因子在实体瘤中表达的系统研究 "的更正。

de Bono JS, Harris JR, Burm SM, Vanderstichele A, Houtkamp MA, Aarass S, Riisnaes R, Figueiredo I, Nava Rodrigues D, Christova R, Olbrecht S, Niessen HWM, Ruuls SR, Schuurhuis DH, Lammerts van Bueren JJ, Breij ECW, Vergote I. 实体瘤中组织因子表达的系统研究。癌症报告。2023;6:e1699.In Table 1 for the data reported in literature for HNSCC, the TF prevalence (%) should read "58%-100%."提到的两篇参考文献（佐证资料文件中的参考文献 18 和 19；佐证资料参考文献）应为：18.Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi BW, Mortensen J, Forman JL, Sorensen AL, Jensen DH, Kjaer A, von Buchwald C. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.BMC Cancer.2017;17: 572.19.Wojtukiewicz MZ, Zacharski LR, Rucinska M, Zimnoch L, Jaromin J, Rozanska-Kudelska M, Kisiel W, Kudryk BJ.喉癌中组织因子和组织因子通路抑制因子的原位表达。Thromb Haemost.1999；82：1659-1662.我们对此错误深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊